000141151 001__ 141151
000141151 005__ 20240229105120.0
000141151 0247_ $$2doi$$a10.1159/000493473
000141151 0247_ $$2pmid$$apmid:30269130
000141151 0247_ $$2ISSN$$a0378-584X
000141151 0247_ $$2ISSN$$a1423-0240
000141151 0247_ $$2ISSN$$a2296-5262
000141151 0247_ $$2ISSN$$a2296-5270
000141151 037__ $$aDKFZ-2018-01682
000141151 041__ $$aeng
000141151 082__ $$a350
000141151 1001_ $$0P:(DE-HGF)0$$aBenzel, Julia$$b0$$eFirst author
000141151 245__ $$aFamilial Pancreatic Cancer.
000141151 260__ $$aBasel$$bKarger$$c2018
000141151 3367_ $$2DRIVER$$aarticle
000141151 3367_ $$2DataCite$$aOutput Types/Journal article
000141151 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1540554332_23500$$xReview Article
000141151 3367_ $$2BibTeX$$aARTICLE
000141151 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141151 3367_ $$00$$2EndNote$$aJournal Article
000141151 520__ $$aFamilial pancreatic cancer accounts for 10% of all patients with pancreatic cancer. Because the 5-year survival rate of pancreatic cancer is only 7%, screening programs for high-risk individuals are essential and might be advantageous. Pancreatic ductal adenocarcinoma mostly shows symptoms at an advanced state and treatment is not efficient enough to cure most patients. People with hereditary tumor syndromes or their affected relatives can also be included in such screening programs. Besides the collection of data to investigate the background of the disease, these screening programs aim to diagnose and treat precursor lesions so that more dangerous, invasive lesions are prevented. These precursor lesions can be pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and mucinous cystic neoplasm. This review summarizes the latest knowledge of pancreatic screening programs, shows the procedure of pancreatic cancer screening, and gives an overview of current guidelines.
000141151 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000141151 588__ $$aDataset connected to CrossRef, PubMed,
000141151 7001_ $$aFendrich, Volker$$b1
000141151 773__ $$0PERI:(DE-600)2749752-5$$a10.1159/000493473$$gVol. 41, no. 10, p. 611 - 618$$n10$$p611 - 618$$tOncology research and treatment$$v41$$x2296-5262$$y2018
000141151 909CO $$ooai:inrepo02.dkfz.de:141151$$pVDB
000141151 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141151 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000141151 9141_ $$y2018
000141151 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000141151 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141151 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141151 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141151 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141151 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOL RES TREAT : 2017
000141151 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141151 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141151 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141151 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141151 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141151 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141151 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141151 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000141151 980__ $$ajournal
000141151 980__ $$aVDB
000141151 980__ $$aI:(DE-He78)B062-20160331
000141151 980__ $$aUNRESTRICTED